Philadelphia, PA, United States of America

Sundarasama Mahalingham

This inventor holds 1 USPTO granted patent. Top assignee: University of Pennsylvania. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sundarasama Mahalingham. Retrieved from https://idiyas.com/inventor/sundarasama-mahalingham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Sundarasama Mahalingham

Introduction

Sundarasama Mahalingham is an accomplished inventor based in Philadelphia, PA. He is known for his significant contributions to the field of molecular biology, particularly in the area of nucleotide sequences.

Latest Patents

Mahalingham holds a patent for "Nucleotide sequences encoding vpr receptor protein." This patent discloses DNA molecules that encode rip-1 protein sequences. Additionally, it includes expression vectors and host cells that incorporate these DNA molecules. He has 1 patent to his name.

Career Highlights

Sundarasama Mahalingham is affiliated with the University of Pennsylvania, where he continues to engage in innovative research. His work has implications for understanding various biological processes and potential therapeutic applications.

Collaborations

He has collaborated with notable colleagues, including David B Weiner and Velpandi Ayyavoo, contributing to advancements in their shared field of research.

Conclusion

Sundarasama Mahalingham's work exemplifies the intersection of innovation and scientific inquiry, making a lasting impact in molecular biology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…